All Posts

by Vista Partners LLC October 2, 2025

Eupraxia Pharmaceuticals Interest Surges With Craig-Hallum Price Target Boost, Clinical Milestones, and Pipeline Expansion -( $EPRX $BMY $AZN $SNY )

Eupraxia Pharmaceuticals (NASDAQ: EPRX) is drawing fresh investor attention as Craig-Hallum raises its price target to $14 following a series of noteworthy pipeline updates and recent clinical trial momentum for its lead asset, EP-104GI, targeting eosinophilic esophagitis (EoE) and broader gastrointestinal indications.

Craig-Hallum Report Highlights

Craig-Hallum’s October 2, 2025, note reiterates a Buy rating for Eupraxia and boosts its price target from $12 to $14, citing EP-104GI’s eventful year ahead, strong clinical data in EoE, and plans to expand the asset to new GI indications in 2026. The report underscores Eupraxia’s robust cash position (~$100M) post-September 2025 offering and clinical runway now stretching into 2028, allowing the company to leverage its proprietary Diffusphere drug delivery technology. Key financial modeling includes projected royalty streams from EP-104IAR in knee osteoarthritis and EP-104GI in Crohn’s disease, estimating total revenues from EP-104 to possibly reach $1 billion by 2035 and $1.7 billion by 2038.

Latest Clinical Momentum

Operational updates in September 2025 confirm first patient dosing in the placebo-controlled Phase 2b portion of the RESOLVE trial for EP-104GI, with topline data expected in H2 2026. The positive nine-month data from cohorts in the Phase 1b/2a dose-escalation segment supports EP-104GI’s promise for durable, deep tissue responses—three patients showed sustained or improved outcomes after nine months, with no serious adverse events. Eupraxia now plans to expand Phase 2b to 120 patients, with critical data readouts in late 2025 and early 2026, reinforcing its leadership in EoE innovation.

Competitive Landscape

EP-104GI’s extended-release, localized delivery mechanism sets it apart from oral or injectable biologics, potentially offering up to 12 months of treatment from a single injection—addressing major pain points like cost, compliance, and repeated administration. This innovation comes as the EoE market, currently dominated by Takeda’s Eohilia and Sanofi’s (SNY) Dupixent, is expected to reach $2.8 billion by 2030. Eupraxia also faces competitive pressure from emerging therapies such as Bristol Myers Squibb’s (BMY) Cendakimab and AstraZeneca’s (AZN) Tezepelumab. Nevertheless, EP-104GI’s unique profile and expanding label opportunities position it as a disruptive contender.

Analyst Consensus and Investor Sentiment

Eupraxia’s stock has seen marked volatility, surging 20% post-market after groundbreaking RESOLVE data in late September 2025. Independent analyst forecasts reflect consensus “Strong Buy” ratings, with price targets as high as $14 (Craig-Hallum), $12 (Chimera Research Group), and $11.50 from broader market consensus, projecting substantial upside from current levels. Analysts cite upcoming clinical catalysts, strong cash reserves, and significant addressable markets as fueling Eupraxia’s investment thesis. Eupraxia’s stock at $5.92 is currently up +124.24% over the last year period.

Looking Forward

With pipeline expansion planned into new GI indications including Crohn’s disease and benign esophageal strictures, Eupraxia is expected to initiate new trials in 2026—potentially unlocking additional revenue streams and opportunities for partnerships. Key risks remain, including clinical, regulatory, and commercial uncertainty, but ongoing investor interest and Wall Street analyst support suggest growing optimism for Eupraxia’s future.

The Sum…

Eupraxia Pharmaceuticals (NASDAQ: EPRX) stands at a strategic crossroads, armed with robust clinical momentum and capital resources, poised to challenge entrenched therapies and redefine long-term care standards in the EoE treatment market and beyond.

The Sources…

by Vista Partners LLC October 2, 2025

OpenAI Completes Record $6.6 Billion Share Sale, Becomes Most Valuable Private Company -( $META $NVDA $SFTBY $TSLA )

OpenAI, the force behind ChatGPT, has shot to the top of the AI world with a record-breaking secondary share sale that now values the company at $500 billion— vaulting it past SpaceX to become the world’s largest startup. The transaction, finalized this week, enabled current and former employees to offload $6.6 billion in shares to an elite investor syndicate including Thrive Capital, SoftBank, Dragoneer Investment Group, Abu Dhabi’s MGX, and T. Rowe Price. This marks a dramatic leap from OpenAI’s $300 billion valuation in its $40 billion funding round earlier this year.

Rush of Investor Enthusiasm

Investor appetite for OpenAI shares has been staggering, with SoftBank committing $40 billion to the company by the end of 2025 if certain milestones are met. Thrive Capital is said to have invested more than $1 billion this round, reportedly gaining unique terms for its commitment. The total tender dwarfed initial company goals, though not all available shares changed hands, as participation rates signal that many insiders remain bullish on the company’s prospects.

Strategic Moves and Global Impact

OpenAI has positioned this share sale not just as a means for liquidity, but as a lever for retaining talent amid frenzied global competition. Meta Platforms (META) is luring AI researchers with compensation packages in the nine-figure range, feeding a heated race for talent and intellectual capital as mega-corporations scramble to build “superintelligence” units.

Meanwhile, strategic partnerships are rippling through global markets. In Korea, memory-chip leaders Samsung and SK Hynix saw their shares surge after clinching deals with OpenAI for the Stargate AI infrastructure project, highlighting OpenAI’s influence beyond Silicon Valley and into the core of global tech supply chains.

Financial Performance and Expansive Goals

OpenAI’s reported $4.3 billion in revenue for the first half of 2025 paces about 16% above its entire 2024 haul, reflecting both explosive user growth and rapid product expansion. New ventures, such as video-generation platforms rivaling TikTok and YouTube, illustrate the company’s ambition to extend AI capabilities well beyond chatbot conversations.

Still, sustainability questions loom. The company faces spending plans in the hundreds of billions as it builds out infrastructure necessary for AI’s next chapter, with chief rivals raising billions—Anthropic recently notched $13 billion at a $183 billion valuation—in a sector some believe is verging on “bubble” territory. OpenAI’s ongoing secondary sales, joining leagues with Elon Musk’s SpaceX, Stripe, and Databricks, underscore its attempt to strike a balance between rewarding employees and staving off the short-term demands of public market.

Market Reaction and the Road Ahead

Investor optimism remains elevated, with the Nasdaq rallying in part due to OpenAI’s headline deals. Yet, challenges remain: how to fund unprecedented AI ambitions, maintain a leading talent roster, and manage mounting infrastructure costs—all while keeping liquidity flowing and sidestepping the tumult of an IPO.

The Sum…

OpenAI’s $500 billion valuation is a signal of AI’s ascendance in global finance and technology. As investor bets swell and strategic partnerships proliferate, the questions for OpenAI—like whether this rate of growth can be sustained or if new AI bubbles may burst—become ever more central to Wall Street’s evolving imagination.

The Sources

by Vista Partners LLC October 1, 2025

Cantor Fitzgerald Analyst Report Highlights Eupraxia’s Market Potential Post Successful Funding – ( $EPRX $IBB $XBI )

Eupraxia Pharmaceuticals (NASDAQ: EPRX) has catapulted into the biotech spotlight following an influential analyst report from Cantor Fitzgerald that reaffirmed its “Overweight” rating and set a robust $11 price target—nearly double the recent public offering price. This endorsement comes on the heels of Eupraxia’s successful $80.5 million capital raise, a significant milestone that secures funding well into 2028, allowing the company to accelerate the clinical and regulatory development of its innovative pipeline.

Major Funding Transforms Clinical Outlook

In late September, Eupraxia concluded a sizeable public offering, pricing 14.6 million shares at $5.50 each and drawing notable participation from specialized life-science investors. Cantor Fitzgerald, which managed the deal alongside LifeSci Capital, highlighted the importance of this infusion, describing it as a “pivotal milestone” that provides both operational flexibility and strategic leverage in navigating the often-volatile biotech landscape. Analysts have underscored that the company now has ample runway to reach key clinical milestones, such as the upcoming Phase 2b data readout for its lead asset EP-104GI, aimed at eosinophilic esophagitis (EoE)—a market with surging diagnostic rates and few effective therapies.

EoE: Expanding Market and Rising Need

EoE, a chronic inflammatory disorder of the esophagus, has seen its U.S. prevalence increase five-fold since 2009; the treated population is now estimated at roughly 159,000. Eupraxia’s EP-104GI leverages the company’s proprietary Diffusphere™ extended-release technology, designed to optimize local drug delivery and limit systemic exposure—potentially positioning it as both “best-in-class” for efficacy and safety. Recent clinical data revealed that patients receiving the highest tested dose experienced the largest improvements in tissue health and eosinophil reduction, leading Eupraxia to expand the Phase 2b RESOLVE trial from 60 to at least 120 patients and select a higher dose for further study. Analysts believe the positive early results and program scale-up bolster the probability of regulatory success and potential breakthrough status.

Financial Strength and Analyst Confidence

Bolstered by the new capital, Eupraxia now boasts a strengthened balance sheet, with analysts citing a substantial cash position and minimal debt. Trading at a market cap near $293 million after a 12-month rally that saw its stock rise over 120%, the company is benefiting from broader sector optimism and a rare consensus among covering analysts, who peg fair value in the $8 to $12 range. Institutional support for the latest fund-raise further validates management’s track record and the commercial promise of its pipeline.

Risks, Execution, and Strategic Positioning

Despite the favorable outlook, Cantor and peer analysts caution that typical sector risks remain—regulatory delays, pipeline concentration, and clinical execution could weigh on future performance. Yet Eupraxia’s expanded clinical program, innovative drug delivery approach, and now-proven ability to access capital markets place it in a strong position as it advances toward key value inflection points over the coming quarters.

The Sum…

With its sights set on additional indications and continued expansion of the EP-104GI program, Eupraxia is now widely viewed as a contender—backed by financial strength and institutional validation—for leadership in targeted, extended-release therapies addressing substantial unmet needs.

Sources

by John F. Heerdink, Jr. September 30, 2025

Join The Tribe Public CEO Series: “Sabotage or Success: Discover How Your Mind Awaits Your Orders” – (Oct. 1, 2025 – 11:30am ET)

Tribe Public extends its appreciation to members who have already registered for this week’s CEO Presentation and Q&A Webinar, scheduled for Wednesday, October 1, at 8:30 a.m. PT / 11:30 a.m. ET. The session, titled “Sabotage or Success: Discover How Your Mind Awaits Your Orders,” will run approximately 30 minutes.

The event will be co-hosted by Nino Fincher, a global authority on Rapid Transformational Therapy (RTT) and Purpose Coaching. RTT, developed by UK-based therapist Marisa Peer, integrates elements of deep relaxation, cognitive-behavioral therapy, and neurolinguistic programming. It has become a widely recognized, solution-oriented method for addressing challenges such as anxiety, depression, insomnia, and post-traumatic stress. Ms. Fincher has worked with a diverse roster of clients, including executives, veterans, artists, athletes, diplomats, and even members of royalty.

Participants are encouraged to submit questions in advance to Research@TribePublic.com. Additional questions may also be raised during the event via Zoom’s chat function.

For those who have not yet registered, details are available at MeetNino.TribePublic.com. Once registered, participants will receive login credentials and a calendar prompt.

Invite attendees are requested to share this opportunity with friends and colleagues, continuing the Tribe’s mission of providing direct access to industry leaders and experts from across disciplines.

by John F. Heerdink, Jr. September 30, 2025

Eupraxia’s Diffusphere Tech Driving Growth And Interest: EOE Clinical Milestone and Big Public Offering

Eupraxia Pharmaceuticals (NASDAQ: EPRX) reported robust clinical results in its highest-dose cohort—8mg per injection—within the ongoing RESOLVE Phase 2b trial for patients with eosinophilic esophagitis (EoE). The pronounced tissue health improvements and eosinophil reduction in Cohort 9 prompted company advisors and safety committees to back the 8mg dose for further study, positioning the formulation as a candidate to redefine how EoE is managed. The firm, leveraging proprietary Diffusphere™ technology, plans to double cohort enrollment to 120 patients, signaling confidence in both efficacy and scalability. Expanded trials are set to reach additional gastrointestinal indications, including Crohn’s disease and benign esophageal strictures, beginning in 2026—a development the company says could meaningfully widen its commercial footprint.

$80.5 Million Public Offering to Fund R&D

On September 24, Eupraxia completed an $80.5 million public equity offering, providing the cash runway needed to see pivotal programs through multiple late-stage milestones. Analysts welcomed the capital infusion, noting that it positions the company to advance its lead candidate EP-104GI through an enlarged Phase 2b trial, expand the R&D portfolio, and fuel regulatory activities, despite the firm’s ongoing net losses and lack of revenue. With this latest fundraising, Eupraxia highlighted its intention to leverage financial flexibility across drug pipeline initiatives and scale-up manufacturing, undeterred by sector-wide volatility.

Independent Directors Increase Their Stakes

Board members, including independent director Joseph Freedman, have recently boosted personal holdings by over 13%, a vote of confidence as Eupraxia embarks on a more ambitious study scale and clinical program expansion. These insider purchases, publicized in financial filings, echo management’s bullishness and may serve as a signal to institutional investors tracking governance and executive skin-in-the-game metrics.

Phase 2b Placebo-Controlled RESOLVE Trial Launches

The transition to the placebo-controlled segment of the EP-104GI RESOLVE trial was announced in August, marking a milestone as the first patients were dosed. Eupraxia expects to report topline data in the second half of 2026. Chief Executive James Helliwell underscored the firm’s commitment to not only meet regulatory endpoints but also to support its claim of superior, sustained efficacy compared to existing therapies. Additional data from Phase 1b/2a cohorts is expected in October, with early results suggesting improved outcomes at nine months for all evaluated subjects.

Sustained EoE Positive Outcomes Highlight Long-Term Benefit

Earlier updates in 2025 celebrated sustained positive treatment outcomes for EoE patients undergoing EP-104GI therapy for nine months. The extended-release attributes—central to Eupraxia’s technology—are highlighted as a differentiator, suggesting that fewer doses and lower systemic exposure may lead to better patient compliance and improved results over conventional therapies.

Diffusphere™ Platform Validated

Alongside patient data, the company spotlighted the wider applicability of its Diffusphere™ platform. The same controlled, localized drug release method is being applied to pursue treatments for post-surgical pain and infection, as well as veterinary indications—each targeting areas where unmet medical need and market opportunity remain sizable.

Analyst Sentiment and Market Position

Recent coverage has trended positive following the financing and clinical news. Analysts have taken a constructive tone, with at least one reiterating a Buy rating with a C$12 price target, though caution persists around profitability and external financing dependence—risks offset in part by the strengthened cash position post capital raise.

Corporate Growth and Outlook

Eupraxia signals that its newest resources and data could facilitate regulatory progress and strategic partnership discussions, potentially shortening time-to-market for EP-104GI and other candidates. As the company prepares for upcoming webinars and investor events, its message to stakeholders is clear: the recent inflection points reflect confidence not only in its technology, but also in its path toward addressing significant therapeutic gaps.

Need More?

For additional context, visit Eupraxia’s website at www.eupraxiapharmaceuticals.com and follow ongoing clinical and financial updates on Nasdaq under the ticker EPRX.

Sources

by John F. Heerdink, Jr. September 29, 2025

Modular Medical Secures $4.4M Seeking to Fast-Track FDA Clearance and Launch Pivot Insulin Patch Pump -( $MODD $LLY $TNDM $MDT )

Modular Medical (NASDAQ: MODD) has made a flurry of strategic moves and operational strides in recent weeks as it works to reshape the landscape of insulin delivery for millions living with diabetes. The company secured approximately $4.4 million in gross proceeds through the exercise of existing warrants, a move that strengthens its financial position and enables further pursuit of FDA clearance for its next-generation Pivot pump technology.

Capital Raise and Strategic Positioning

Modular Medical’s recent $4.4 million capital infusion, achieved by incentivizing warrant holders with a reduced exercise price and additional unregistered warrants, highlights continued investor confidence in its targeted approach to the $3 billion adult “almost-pumpers” market. These adults require daily insulin injection but have largely shunned traditional, complex insulin pumps. This capital is slated for working capital and general corporate purposes, with a sharpened focus on advancing the FDA clearance pathway for the Pivot product.

Advancing Product Development: MODD1 and Pivot

The company’s efforts on the manufacturing front are equally notable. Modular Medical recently completed production of over 6,000 cartridges for its MODD1 patch pump, validating its platform for high-volume manufacturing. With this operational milestone, the manufacturing line is now being converted for Pivot-ready production ahead of a planned 510(k) submission to the FDA in October 2025. The Pivot device promises to be the first tubeless, removable 3 mL patch available to consumers, emphasizing user-friendliness and affordability — both critical differentiators in a market that demands simplicity.

Clinical validation remains front-and-center. Modular Medical successfully completed a real-world deployment study of the MODD1 pump with clinicians living with Type 1 diabetes, providing essential experience and feedback for refining the Pivot system. Additionally, the company received IRB approval to commence a feasibility study for the Pivot pump, which will assess usability and extended wear in adult participants over a 90-day period. These studies are designed to optimize both product experience and design before broader commercial launch.

Leadership and Strategic Vision

To guide its growth and mission, Modular Medical has bolstered its board with the addition of Jeff Goldberg, a proven leader in life sciences and medical device innovation, particularly in generic insulin and patch pumps. The executive team is distinguished by decades of combined expertise in diabetes care, device engineering, finance, and large-scale manufacturing, led by founder Paul DiPerna and CEO Jeb Besser.

Company Mission and Market Opportunity

Founded in San Diego in 2017, Modular Medical is driven by a simple mission: to democratize access to superior diabetes care technology. Its vision focuses on simplifying diabetes management with intuitive, affordable devices targeting the millions who are underserved by current pump technologies. With 1.9 million Americans living with Type 1 diabetes—and less than a third currently using insulin pumps—the addressable market is vast. Modular Medical’s lean operating model and proprietary technology pipelines position it to expand into broader diabetes management solutions in the future

Community Engagement and Next Steps

The company’s momentum is reflected not only in its operational milestones but also in its outreach, with a recent webinar presentation featuring CEO Jeb Besser highlighting Modular Medical’s commitment to making diabetes management simpler and more accessible. As the Pivot pump approaches regulatory review and anticipated launch, the company remains dedicated to fostering a community where diabetes care is empowering, not intimidating.

Competitive Landscape & Potential Suitors

The insulin pump market is highly competitive, with several major players dominating through advanced technology, broad distribution, and continuous product innovation. Medtronic plc (MDT) leads with its advanced closed-loop MiniMed systems, focusing on integrated diabetes management. Insulet Corporation’s (PODD) Omnipod patch pump is a market leader in tubeless, wearable insulin delivery, popular in both adult and pediatric segments. Tandem Diabetes Care (TNDM) has gained prominence for its sleek, user-friendly t:slim X2 pump and strong CGM (continuous glucose monitoring) integration, appealing to tech-savvy users seeking flexible therapy and real-time data.

F. Hoffmann-La Roche brings extensive expertise in precision dosing and connectivity, while Ypsomed AG is recognized for modular, interoperable pump designs, primarily in Europe and expanding globally. Sooil Development Co. (DANA series), Valeritas Holdings (V-Go wearable patch for type 2 diabetes), and Bigfoot Biomedical (cloud-based, data-driven pump systems) round out other prominent competitors. Recent years have also seen increased digital integration and a push toward affordability and simplicity, with companies like Cellnovo and Debiotech investing in compact, user-friendly solutions.

The competitive landscape is further shaped by regional players, as well as established pharmaceutical firms like Novo Nordisk, Eli Lilly (LLY), and Sanofi, who lead the broader insulin delivery market through pen and pump innovation. North America remains the largest market, but Asia-Pacific is experiencing the fastest growth due to rising diabetes prevalence and healthcare infrastructure investment.

The Sum…

In sum, Modular Medical (NASDAQ: MODD) stands at a pivotal juncture, leveraging new capital, sound leadership, and validated manufacturing to drive forward the commercialization of patch pump technology designed for everyday use. Its ongoing studies, manufacturing execution, and vision for inclusivity may redefine how millions approach diabetes management in the coming years.

The Sources

by John F. Heerdink, Jr. September 29, 2025

Jennifer Garner’s Once Upon a Farm Files for NYSE IPO: Transforming Kids’ Nutrition with Farm-Fresh Values – ( $OFRM $GS $JPM $BAC )

Once Upon a Farm, the organic baby and kids’ food pioneer co-founded by actress Jennifer Garner, officially filed for an initial public offering on the New York Stock Exchange this week, signaling a remarkable milestone for a brand that has fused celebrity cachet with authentic agricultural values and modern nutrition standards. The offering—under the ticker symbol “OFRM”—is led by heavyweight underwriters Goldman Sachs (GS), J.P. Morgan (JPM), BofA Securities (BAC), and William Blair.

Roots in Family and Mission

Founded in 2015 by Cassandra Curtis and Ari Raz, with Garner and former Annie’s CEO John Foraker joining in 2017, Once Upon a Farm was born of a desire to elevate childhood nutrition using real, organic ingredients sourced from trusted farms—including Garner’s own century-old family property in Locust Grove, Oklahoma. The company’s founding ethos is visible in its hands-on approach: Garner, a mother of three, oversees elements of farm production and community engagement, leveraging the family farm’s legacy to reinforce the brand’s authenticity.

“We’re connecting kids to the farm, and it gets to be my family’s farm that’s been with us since 1936,” Garner has said, highlighting Once Upon a Farm’s commitment to making wholesome food accessible while preserving agricultural heritage.

Growth, Innovation, and Social Impact

Once Upon a Farm has rapidly transformed from local retail beginnings into a leading voice in the packaged organic kids’ food sector. Its signature product: cold-pressed, organic fruit and veggie blends, revolutionized the category by introducing refrigerated pouches with no added sugar, preservatives, or artificial ingredients—crafted for babies’ first bites and school-age snacks alike.

Revenue has climbed from less than $1 million to well north of $100 million annually, fueled by a series of funding rounds—including a $52 million Series D—and expansion beyond baby food into oat bars and dairy snacks. This strategic shift taps into a kids’ food market that far surpasses baby food in both scale and potential.

The company also touts its environmental and social credentials: Once Upon a Farm is a certified B Corporation, producing with renewable energy, and has partnered with Save the Children to provide a million meals to children in need by 2024. The brand’s mission-driven model intertwines business performance with community outreach, setting a contemporary standard for purpose-led consumer goods companies.

IPO Outlook and Industry Context

The IPO filing occurs amid a renewed wave of public offerings in the U.S. market, positioning Once Upon a Farm for a possible $1 billion valuation. Backed by standout revenue growth and a distinct vision, the company aims to capture investor attention with its blend of innovation, social responsibility, and farm-fresh authenticity.

The Sum…

As Once Upon a Farm embarks on its next chapter, it stands as a case study in transforming nostalgia and nutrition into shareholder value—a narrative rooted in the soil of Oklahoma and delivered, fresh, to families nationwide.

Sources

by John F. Heerdink, Jr. September 26, 2025

Serina Therapeutics CEO: Why Now Is the Time to Invest in Biotech – ( $SER $IBB $XBI )

In a video released this week, Serina Therapeutics’ (NYSE American: SER) Chief Executive Officer Steven Ledger outlined what he described as a rare convergence of factors for biotech investing, highlighting both daunting market conditions and an emerging window of opportunity.

Watch Now

Market Backdrop Sets the Stage

Ledger, speaking amid the biotech sector’s fifth consecutive year of a historic downturn, highlighted how capital scarcity is reshaping the industry landscape. Only firms with robust backing and diversified portfolios, such as Serina, have continued to attract investment. Ledger asserts that “the companies able to attract capital must have something special,” prompting investors to concentrate on organizations with strategic support and multiple clinical “shots on goal”.

Historic Undervaluation Persists

The CEO further called attention to the increasing number of biotech firms trading at negative enterprise values—meaning they hold more cash than their market caps. Ledger noted, “Investors are giving very little credit to what they might be doing with that precious capital,” referring to a market dynamic that historically signals sector recovery may be approaching.

Generalist Investors on the Sidelines

As risk-off sentiment prevails due to macroeconomic challenges, generalist investors have stepped back from biotech. For now, the sector is dominated by specialists, but Ledger suggests that as sentiment turns and capital flows return, companies prepared with both strategic capital and product pipelines could benefit disproportionately when generalist investors re-enter the space.

Serina’s Clinical and Financial Progress

Amid these sector trends, Serina Therapeutics has secured up to $20 million in milestone-based financing to advance the registrational Phase 1b trial of SER-252, its lead candidate for advanced Parkinson’s disease that was led by Serina Board Director Greg Bailey, MD. “I continue to invest in Serina because of my confidence in the management team, my enthusiasm for their lead candidate, and the compelling 505(b)(2) approval path for SER-252 and potentially other products enabled by Serina’s technology. The recent FDA feedback provides a clear and efficient route to registration, positioning SER-252 for a highly capital-efficient NDA submission. This financing will drive pivotal milestones, and most importantly, I believe SER-252 could become a best-in-class therapy for the 180,000 advanced Parkinson’s patients in the US and Europe whose symptoms remain poorly controlled by current treatments,” said Greg Bailey, MD, Board Member of Serina and Co-Founder and Executive Chairman of Juvenescence.

Following positive feedback from the FDA, the company will pursue a 505(b)(2) NDA pathway, which leverages existing data on approved drugs to speed regulatory review and approval. Serina aims to start patient dosing in Australia in Q4 2025, with U.S. enrollment to follow in Q1 2026. The trial design utilizes randomized, double-blind, placebo-controlled methods to robustly assess motor fluctuation outcomes in advanced Parkinson’s patients.

Alongside this, Serina is advancing SER-270, a once-weekly injectable therapy targeting tardive dyskinesia, and has begun evaluating its platform for treating Huntington’s disease chorea, continuing to expand its reach into movement disorders.

Eyes on the Horizon

Ledger’s remarks underscore a bullish stance for biotech investing, as Serina Therapeutics (SER) positions itself with robust financing, a streamlined path to regulatory milestones, and a diversified pipeline. With capital scarce, valuations compressed, and broad-market investors awaiting signals to return, the company aims to seize pivotal growth opportunities as sentiment and capital flows shift back toward innovation-driven development.

Serina’s POZ Platform

Serina’s proprietary POZ Platform™ is based on a synthetic, water soluble, low viscosity polymer called poly (2-oxazoline). During the synthesis steps, a predictable amount of drug is incorporated on the backbone of the polymer using pendant alkyne groups and metal catalyzed “click chemistry”. The POZ Platform ™ technology provides greater control in drug loading, and the rate of release of attached drugs can often be more precisely controlled. Drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood. The technology is optimized for small molecules and can also be applied to other classes of molecules including proteins and peptides. The application of the platform has been further expanded to optimize the performance of antibody drug conjugates and lipid nanoparticles.

Sources

by John F. Heerdink, Jr. September 26, 2025

Palsonify FDA Greenlight: Crinetics Seeks to Launch Oral Therapy for Acromegaly Patients – ( $CRNX $IBB $XBI )

San Diego, CA based Crinetics Pharmaceuticals (CRNX) delivered a watershed moment on Friday as the FDA granted approval of Palsonify (paltusotine), the first once-daily, oral therapy for acromegaly—a rare hormonal disorder—propelling shares to their strongest session of the year. On Friday, Crinetics stock leapt ~+24% to $46.11 after trading near $35 prior to the announcement, making it the top gainer among U.S. biotech stocks for the day., but it is still down approx. 11% YTD.

Analyst Commentary and Forecasts

Sell-side analysts responded decisively. JMP Securities lifted its price target from $86 to $143, citing Palsonify’s clean label and transformative potential as a standard of care therapy for acromegaly. Oppenheimer reiterated its Outperform rating, pointing out that while the annual wholesale acquisition cost of $290,000 exceeded consensus expectations, the absence of major label restrictions and strong clinical data augur well for rapid uptake. Eight analysts currently rate Crinetics as a Buy or Outperform, with consensus estimates for 12-month price targets ranging from $35 to $143. Technical signals are reportedly bullish, but neutral sentiment is observed based on longer-term profitability concerns.

Commercial Rollout and Market Dynamics

Palsonify is expected to be available in early October, supported by CrinetiCARE services to enhance patient access and adherence. Entering a market dominated by injectable therapies, the company is betting its oral formulation will drive adherence and market share capture. The FDA approval, clean labeling, and indication for adults across a wide patient spectrum validate Crinetics’ small molecule platform and elevate its profile among endocrine-focused peers.

Pipeline Prospects and Industry Response

Crinetics’ pipeline, including treatments for congenital adrenal hyperplasia and carcinoid syndrome, now carry less regulatory risk with Palsonify’s nod. Analysts expect this momentum and the strong cash position to fuel future expansions and acquisitions in fragmented endocrine therapy markets.

The Sum…

Crinetics Pharmaceuticals (CRNX), with its landmark Palsonify approval, has turned a corner from underperformance to leadership, buoyed by bullish analyst sentiment and game-changing clinical data, poised to redefine care standards for rare endocrine diseases.

Sources

by John F. Heerdink, Jr. September 25, 2025

Cantor Fitzgerald Analyst Report Drives Biotech Buzz About Eupraxia After Major Funding – ( $EPRX $IBB $XBI )

Cantor Fitzgerald has recently updated their coverage of Eupraxia Pharmaceuticals (NASDAQ: EPRX) with an “Overweight” rating and an $11 target price—a move that places the emerging biotech on the radar of institutional investors seeking innovation in the field of locally delivered, extended-release therapeutics. Eupraxia’s proprietary Diffusphere™ technology, designed to optimize drug delivery with prolonged activity and reduced systemic side effects, is positioning the company at the forefront of efforts to address chronic diseases where local control and improved pharmacokinetics may translate into better outcomes.

Capital Raise and Analyst Focus

The publication of Cantor’s report follows a string of pivotal developments for Eupraxia Pharmaceuticals (NASDAQ: EPRX). The company recently closed an $80.5 million public offering, pricing 14.6 million shares at $5.50 each. Cantor Fitzgerald, together with LifeSci Capital, managed the deal, which extended Eupraxia’s capital runway into 2028 and put the company in a strong financial position for advancing its clinical programs. Analysts point to this fundraising as a crucial lever in supporting ongoing studies, including the Phase 2b trial of EP-104GI for eosinophilic esophagitis (EoE)—a chronic inflammatory disorder of the esophagus with increasing diagnosis rates and limited treatment options.

Technology Platform and Clinical Prospects

Cantor Fitzgerald’s bullish stance is underpinned by the promise of Eupraxia’s Diffusphere™ platform. This technology enables controlled, localized drug release, addressing limitations of existing systemic therapies and seeking to improve both efficacy and safety for conditions like EoE. Recent clinical results from a trial in EoE demonstrated sustained positive treatment outcomes without serious adverse events, bolstering analyst confidence. At 12 months, 2/3rds of Cohort 5 patients (48mg dose, 4mg per site) remained in clinical remission after their treatment with EP-104GI. Dr. James A. Helliwell, Chief Executive Officer of Eupraxia stated, “We believe the prolonged duration of symptom response that we are seeing with EP-104GI is truly a unique clinical result and will potentially provide a once-a-year therapy to patients with EoE. And overall, we continue to see that the more drug we deliver to the tissues, the better the results. Independent market research has shown that the majority of patients with EoE undergo a routine endoscopy at least once a year to monitor the progress of their disease, which is also consistent with national guidelines. Based on this, leading KOLs in EoE see a potential treatment regimen where EP-104GI is administered during this routine annual procedure, in contrast to current standards of care which are inconvenient and involve swallowing oral steroids daily or injecting themselves weekly with a biologic. As a result, we believe EP-104GI has the potential to significantly enhance the current standard of care for patients with EoE. We look forward to reporting additional 12-month data from a larger patient set later this year.”

Valuation and Market Context

With the Cantor report assigning an $11 price target—well above the offering price—the endorsement reflects institutional belief in both pipeline potential and management’s ability to execute. Other analysts echo this optimism, with consensus “Buy” ratings and price targets generally in the $8–$12 range. The participation of specialized life-science investors in the capital raise adds further validation to the company’s business model and innovation roadmap.

Risks and Considerations

Despite the positive momentum, Cantor and others acknowledge Eupraxia faces typical biotech sector risks: pipeline concentration, regulatory hurdles, and the ever-present execution risk in clinical development. However, with expanded funding and a differentiated platform in a high-need area, the company is viewed as favorably positioned for the next evolution in its growth story.

How To Get The Complete Report

To request a full copy of the Cantor Fitzgerald report on Eupraxia Pharmaceuticals (EPRX), institutional investors and interested parties can contact the Cantor Fitzgerald Equity Research team directly through their company website’s contact form. Specialist analysts covering biotechnology at Cantor Fitzgerald include Kristen Kluska and Richard Miller, Ph.D.—both reachable via Cantor Fitzgerald’s New York headquarters at 110 East 59th Street, New York, NY 10022, or by calling (212) 938-5000.

For direct inquiries by email, potential report recipients should use cfsupport@cantor.com or submit their request through the research department’s official channel at Cantor.com. BioPharma Equity Research Associate Sarah Medeiros is another point of contact for biotech-focused equity research requests at Cantor Fitzgerald.

Provide relevant professional or institutional details when reaching out to expedite your request.

Craig-Hallum Report Highlights

Latest Clinical Momentum

Competitive Landscape

Analyst Consensus and Investor Sentiment

Looking Forward

The Sum…

The Sources…

Rush of Investor Enthusiasm

Strategic Moves and Global Impact

Financial Performance and Expansive Goals

Market Reaction and the Road Ahead

The Sum…

The Sources

Major Funding Transforms Clinical Outlook

EoE: Expanding Market and Rising Need

Financial Strength and Analyst Confidence

Risks, Execution, and Strategic Positioning

The Sum…

$80.5 Million Public Offering to Fund R&D

Independent Directors Increase Their Stakes

Phase 2b Placebo-Controlled RESOLVE Trial Launches

Sustained EoE Positive Outcomes Highlight Long-Term Benefit

Diffusphere™ Platform Validated

Analyst Sentiment and Market Position

Corporate Growth and Outlook

Need More?

Sources

Capital Raise and Strategic Positioning

Advancing Product Development: MODD1 and Pivot

Leadership and Strategic Vision

Company Mission and Market Opportunity

Community Engagement and Next Steps

Competitive Landscape & Potential Suitors

The Sum…

The Sources

Roots in Family and Mission

Growth, Innovation, and Social Impact

IPO Outlook and Industry Context

The Sum…

Sources

Watch Now

Market Backdrop Sets the Stage

Historic Undervaluation Persists

Generalist Investors on the Sidelines

Serina’s Clinical and Financial Progress

Eyes on the Horizon

Serina’s POZ Platform

Sources

Analyst Commentary and Forecasts

Commercial Rollout and Market Dynamics

Pipeline Prospects and Industry Response

The Sum…

Sources

Capital Raise and Analyst Focus

Technology Platform and Clinical Prospects

Valuation and Market Context

Risks and Considerations

How To Get The Complete Report

Sources

Your Guide To Staying Informed In The Markets